Ollin Biosciences to Participate in Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY

Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI

About Ollin Biosciences

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526926052/en/

Media:
Katie Engleman
1AB
[email protected]

Source: Ollin Biosciences, Inc.

You May Also Be Interested In

• Faraday Future Announces FF EAI Robotics’ Employee Incentive Plan to Allocate Approximately 25% of Its Outstanding Shares for Stock Options for Its Core Team, Aiming to Establish an Industry-First P
• KBRA Assigns AA+ Rating to Various State of Connecticut General Obligation Bonds; Affirms Rating for Parity Bonds
• Resources Connection to Announce First Quarter Fiscal 2027 Results on October 7, 2026